Overview

Latino Semaglutide Study

Status:
Not yet recruiting
Trial end date:
2022-08-14
Target enrollment:
Participant gender:
Summary
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Phase:
Phase 3
Details
Lead Sponsor:
Warren Peters, MD, MPH
Collaborator:
Novo Nordisk A/S